Florida hospitals lose $2B opioid lawsuit against pharmacies
Ella Jeffries / beckershospitalreview - A Florida judge has ruled in favor of CVS, Walgreens and Walmart in a lawsuit brought by 16 hospitals seeking $2 billion in damages related to the opioid epidemic. Broward County Chief Judge Carol-Lisa Phillips entered judgment for the defendants May 26, …
AI Summary: A Florida court ruling overturned a multibillion‑dollar claim by hospitals against major pharmacy chains, finding in favor of CVS, Walgreens and Walmart in litigation tied to the opioid epidemic. The decision removes a major anticipated payout and reshapes liability questions in the national effort to hold corporate actors accountable for addiction harms — legal teams are predictably thrilled.
One-time gene editing treatment lowers 'bad' cholesterol by up to 62%
medicalxpress - Patients in London have received a pioneering new gene editing therapy that lowers "bad" cholesterol after a single infusion, as part of a study involving UCL scientists.
AI Summary: Early clinical data show a one‑time gene‑editing infusion can reduce LDL cholesterol by as much as 62% in patients with severe hypercholesterolemia. The approach, still experimental, produced large lipid drops with early safety signals, hinting at a possible future one‑and‑done therapy for high‑risk cardiovascular patients — pending larger trials and careful long‑term follow‑up.
MAGE-A4/MAGE-A8-targeted TCR-based bispecific T cell engager in recurrent and/or refractory solid tumors: a phase 1 trial
Martin Wermke / nature - Nature Medicine, Published online: 31 May 2026; doi:10.1038/s41591-026-04455-xAs presented at the 2026 ASCO Annual Meeting, in a prespecified interim analysis of a phase 1a trial of IMA401—a new bispecific TCR-based T cell engager that binds a MAGE-A4/MAG…
AI Summary: A phase 1 trial of a TCR‑based bispecific T‑cell engager targeting MAGE‑A4 and MAGE‑A8 demonstrated early anti‑tumor activity in recurrent or refractory solid tumors, with an acceptable safety profile in dose‑finding cohorts. These results revive interest in targeting intracellular cancer antigens via T‑cell redirection, nudging immunotherapy beyond familiar checkpoint territory.